Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed)
The summary for the Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed): The purpose of this Funding Opportunity Announcement (FOA) is to accelerate development of safe and effective long-acting drug delivery systems (LA-DDS) for improved, simplified treatment of HIV-1 in children. This FOA invites applicants engaged in the development of existing LA-DDS platforms at early product development stages to perform specific preclinical activities that enable product optimization and accelerated translation to HIV-1 infected children. Collaborative research partnerships with industry are required.
|Federal Grant Title:||Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed)|
|Federal Agency Name:||National Institutes of Health (HHS-NIH11)|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-AI-18-057|
|Type of Funding:||Grant|
|CFDA Descriptions:||Information not provided|
|Current Application Deadline:||March 13th, 2019|
|Original Application Deadline:||March 13th, 2019|
|Posted Date:||November 20th, 2018|
|Creation Date:||November 20th, 2018|
|Archive Date:||April 18th, 2019|
|Total Program Funding:||$3,860,000|
|Maximum Federal Grant Award:|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
|Last Updated:||November 20th, 2018|
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Link to Full Grant Announcement
- Grant Announcement Contact
- NIH OER Webmaster
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- Similar Government Grants
- • Accelerating Discovery of Efficacious Pre-erythrocytic Stage Malaria Vaccines (U01 Clinica...
- • Understanding Phage Biology to Support the Development of Bacteriophage Therapy (R21 Clini...
- • Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01 Clinical T...
- • NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)
- • Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01 C...
- • Center for HIV/AIDS Vaccine Immunology (CHAVI)
- • Genomics of Transplantation Cooperative Research Program
- • Asthma and Allergic Diseases Cooperative Research Centers
- More Grants from the National Institutes of Health
- • Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
- • A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
- • Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
- • HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
- • National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan...